LBRX LB PHARMACEUTICALS INC

8-K Current Report
Filed: March 16, 2026
Health Care
Pharmaceutical Preparations

LB PHARMACEUTICALS INC (LBRX) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

  • Zachary Prensky retiring from LBRX Board, not standing for reelection at 2026 Annual Meeting; no disagreement with company operations or policies
  • Prensky transitions to consulting role post-departure under amended Transition Agreement (originally dated Nov 26, 2024), effective June 3, 2026
+2 more insights

Other LB PHARMACEUTICALS INC 8-K Filings

Get deeper insights on LB PHARMACEUTICALS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.